KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) Equity Average: 2009-2025

Historic Equity Average for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Sep 2025 value amounting to $6.0 billion.

  • Biomarin Pharmaceutical's Equity Average rose 12.94% to $6.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 billion, marking a year-over-year increase of 12.94%. This contributed to the annual value of $5.3 billion for FY2024, which is 11.04% up from last year.
  • According to the latest figures from Q3 2025, Biomarin Pharmaceutical's Equity Average is $6.0 billion, which was up 2.23% from $5.9 billion recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's Equity Average registered a high of $6.0 billion during Q3 2025, and its lowest value of $4.1 billion during Q1 2021.
  • Its 3-year average for Equity Average is $5.3 billion, with a median of $5.2 billion in 2024.
  • Data for Biomarin Pharmaceutical's Equity Average shows a peak YoY grew of 29.95% (in 2021) over the last 5 years.
  • Over the past 5 years, Biomarin Pharmaceutical's Equity Average (Quarterly) stood at $4.3 billion in 2021, then increased by 7.50% to $4.6 billion in 2022, then increased by 7.38% to $4.9 billion in 2023, then increased by 12.42% to $5.5 billion in 2024, then climbed by 12.94% to $6.0 billion in 2025.
  • Its Equity Average stands at $6.0 billion for Q3 2025, versus $5.9 billion for Q2 2025 and $5.7 billion for Q1 2025.